RecruitingNot ApplicableNCT06462157

Group Compassionate Mind Training for Adults Experiencing the Menopause Transition

The Feasibility and Effects of Group Compassionate Mind Training for Adults Experiencing the Menopause Transition: a Preliminary Investigation


Sponsor

University College, London

Enrollment

40 participants

Start Date

Jun 20, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Menopause transition occurs naturally for women aged 45-55. In addition to the hormone changes, there are often changes in other areas of life including low mood, anxiety, 'brain fog' and embarrassment. Some people may not be eligible for or want to receive hormone replacement therapy, therefore psychological treatments for menopause have been investigated. There is growing evidence for the use of Compassionate Mind Training (CMT). CMT aims to reduce feelings of self-criticism and shame which are commonly reported by adults experiencing the menopause, by helping individuals to take better care of themselves, known as self-compassion. Findings show menopausal individuals who are more self-critical may be more vulnerable to difficulties during menopause. Therefore, CMT could help manage this. CMT improves self-compassion and reduces depressive symptoms, with group formats found to be more effective than individual or self-help. A previous study of online self-help CMT for the menopause received positive feedback for the therapy and people improved in several areas including self-compassion. Clearly, there could be benefits to offering CMT as a treatment for menopause. Given that group CMT is effective in other populations and groups are more economical and practical for the NHS, this study is interested in looking at the impact of group CMT on menopause. This study aims to find out how practical and suitable group CMT is for improving the wellbeing of adults experiencing the menopause, and what their views are on the therapy and taking part in the study. To measure the aims, we will look at the ease of recruiting people to the study, whether they are happy to be randomly allocated to receive the therapy or not, whether they stay in the study, the number of completed questionnaires and feedback from participants. It will also look at whether there have been any changes in different domains e.g. anxiety and self-compassion. This will be done through a variety of quantitative and qualitative outcomes.


Eligibility

Sex: FEMALEMin Age: 40 YearsMax Age: 60 Years

Inclusion Criteria8

  • Adults (aged 40-60) who are biologically female
  • Women who are experiencing symptoms of the menopause or peri-menopause; which is naturally occurring. This is identified through the STRAW criteria. Individuals have to answer Yes on at least one of the STRAW screening questions to ensure women are in the perimenopause or menopausal period.
  • Substantial English verbal communication and comprehension skills
  • Capacity to consent
  • Confident in using video conferencing applications (MsTeams)
  • Willingness to take part in a post-intervention interview about their experience.
  • PHQ-9 score 5-19 (mild to moderate clinical cut offs)
  • GAD-7 score 5-15 (mild to moderate clinical cut offs)

Exclusion Criteria6

  • People under the age of 40
  • People currently receiving any form of psychology intervention.
  • Transgender females who are biologically male
  • More than 5 years post menopause.
  • PHQ-9 score greater or equal to 20 (severe clinical cut off)
  • GAD-7 score greater or equal to 15 (severe clinical cut off)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERCompassionate Mind Training

Participants will attend 6 x 90-minute online CMT sessions. CMT is delivered by combining taught information, exercises, and practices. It is effective, so the aim is to explore its use with menopausal women.


Locations(1)

University College London

London, County, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06462157


Related Trials